What markers track visceral fat?
Visceral fat is tracked in research by imaging-based fat fraction and by circulating adipokines and cytokines. This page summarises the markers and models named in the evidence.
Visceral fat, also called visceral adipose tissue (VAT) or intra-abdominal fat, is the adipose depot surrounding internal organs. In the research literature it is quantified by imaging—most often magnetic resonance imaging (MRI) proton density fat fraction (PDFF) or magnetic resonance–derived visceral fat area—and by anthropometric or bioelectrical impedance analysis (BIA) estimates. No single molecular formula or sequence defines visceral fat; it is a tissue compartment, not a compound. The markers that track it are therefore either imaging endpoints or circulating proteins whose concentrations are compared against those endpoints.
The work centres on adipokine and cytokine signalling—leptin, resistin, sclerostin, irisin, and inflammatory mediators—and on incretin receptor pathways, particularly glucagon-like peptide-1 receptor (GLP-1R) agonism and dual GLP-1/glucagon receptor agonism, which are being tested against visceral and ectopic fat endpoints.
Research Studies
Mazdutide and pancreatic fat fraction in overweight or obesity
A randomised, double-blind, placebo-controlled, parallel-group, single-centre trial is evaluating mazdutide for fatty pancreas in adults with overweight or obesity. The study plans to enrol 194 participants, randomised 1:1 to mazdutide plus standardised lifestyle intervention or placebo plus standardised lifestyle intervention, for 48 weeks. The primary efficacy endpoint is change from baseline in pancreatic proton density fat fraction (PDFF) measured by MRI at week 48; secondary endpoints include changes in body composition [1].
Mazdutide and visceral fat in type 2 diabetes with NAFLD
A multicentre, prospective, randomised controlled investigator-initiated trial is evaluating a switch to mazdutide in Chinese patients with type 2 diabetes mellitus (T2DM) and moderate-to-severe non-alcoholic fatty liver disease (NAFLD) who have achieved glycaemic control. The background states that Chinese patients with T2DM are susceptible to visceral fat accumulation, which increases cardiometabolic risk and mortality, and that metabolic associated fatty liver disease (MAFLD) is highly prevalent in this group [2].
Sclerostin, irisin and leptin and body composition in Chinese men with obesity
A cross-sectional study included 26 men with normal weight and 78 men with obesity. Body composition was measured by dual-emission X-ray absorptiometry; subcutaneous fat, visceral fat, and fat content in the liver and pancreas were determined by MRI; and serum sclerostin, irisin and leptin were measured by ELISA. Compared with men with normal weight, serum sclerostin, irisin and leptin levels differed, alongside whole-body and spinal bone mineral density [3].
BMI versus BIA-derived body composition and IVF outcomes
A prospective observational cohort study is assessing whether body composition measured by bioelectrical impedance analysis (BIA)—including body fat percentage and visceral fat—predicts in vitro fertilisation (IVF) outcomes better than body mass index (BMI). Participants undergo BIA before treatment. Outcomes of interest include ovarian stimulation requirements, number of mature oocytes retrieved, and number of oocytes fertilised [4].
Urolithin A and muscle preservation during restricted eating in obesity
A trial is testing whether daily urolithin A (500 mg) for 6 months helps adults with obesity lose weight while preserving functional muscle mass and improving markers of mitochondrial health, inflammation, and metabolism. All participants receive the same structured lifestyle programme; half receive urolithin A and half a matching placebo. The background notes that weight loss can reduce skeletal muscle, especially in people with obesity, and links ageing and obesity to mitochondrial dysfunction, impaired autophagy/mitophagy, oxidative stress, and low-grade inflammation [5].
Resistin and visceral fat reduction after sleeve gastrectomy
A study is investigating whether serum resistin can predict how much visceral fat a patient loses after sleeve gastrectomy for morbid obesity. The background describes visceral fat as fat stored around internal organs, closely linked to inflammation and type 2 diabetes, and describes resistin as a marker that contributes to insulin resistance and is typically higher in individuals with significant abdominal fat. Resistin is measured before surgery [6].
Barley green and visceral fat area in high body fat percentage
A randomised study at Peking University People's Hospital investigated changes in visceral fat area and associated indicators in individuals with high body fat percentage under barley green intervention, and explored mechanisms via gut microbiota analysis. The intervention group received barley green supplementation with a calorie-restricted diet [7].
Ethnic differences in adipose tissue dysfunction and insulin resistance
A pilot study is investigating the relationship between type 2 diabetes and adipose tissue dysfunction across ethnic groups. Adipose tissue dysfunction is characterised by abnormal fat distribution, including increased visceral, hepatic, and pancreatic fat, elevated inflammatory biomarkers, and impaired metabolic function. The background notes that in the UK, type 2 diabetes prevalence is significantly higher among South Asian and Black African/Caribbean populations than among White Europeans, and that differences in visceral fat accumulation are thought to contribute [8].
Markers compared across studies
| Marker or measure | What it tracks | Model or population |
|---|---|---|
| Pancreatic PDFF (MRI) | Fat fraction in pancreas | Adults with overweight or obesity [1] |
| Visceral fat area (MRI) | Intra-abdominal fat area | High body fat percentage [7] |
| Visceral fat (BIA) | Estimated visceral fat | People undergoing IVF [4] |
| Resistin | Insulin resistance marker | Morbid obesity, sleeve gastrectomy [6] |
| Sclerostin, irisin, leptin | Bone, muscle and fat-derived factors | Chinese men with obesity [3] |
| Inflammatory biomarkers | Adipose tissue dysfunction | Ethnic groups with T2D [8] |
If you are reading this for personal health reasons
The materials described here are sold for laboratory research only. We do not provide dosing, medical guidance, or any recommendation for personal use. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Efficacy of Mazdutide on Fatty Pancreas
- [2] Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
- [3] Serum Bone-, Muscle- and Fat- Derived Factors Sclerostin, Irisin and Leptin Show Different Correlations With Body Composition and Bone Mineral Density in Chinese Men With Obesity: A Cross-Sectional Study.
- [4] BMI Versus Body Fat Percentage - Which is the Better Predictor of Fertility Outcomes in IVF Cycles?
- [5] Influence of the Urolithin A on the Population With BMI Higher Than 30 During Restricted Eating.
- [6] Relationship Between Serum Resistin Levels and Reduction in Visceral Fat in Patients Undergoing Sleeve Gastrectomy Due to Morbid Obesity
- [7] Effects of Barley Green on Visceral Fat Area in the Human Body and Investigation Into the Associated Mechanism of Intestinal Microbiota
- [8] Ethnic Differences in Adipose Tissue Dysfunction in the Development of Insulin Resistance and Type 2 Diabetes
- [9] Circulating Adipokines, Tissue Receptor Expression, and Body Composition: Clinical Relevance and Disease Stage in Epithelial Ovarian Carcinoma.
- [10] Bitter hop nutraceutical stimulates fat mass loss while preserving muscle mass in a cohort of individuals with overweight or obesity receiving diet and exercise advice.
- [11] Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists.
- [12] Hematopoietic stem cell transplantation-associated partial lipodystrophy.